Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC

November 12th 2014

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Dr. Chu Discusses CNS Penetration of Ceritinib

November 12th 2014

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.

Immunotherapies Continue to Impress in NSCLC Trials With Several Forecast for Approval

November 10th 2014

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

With Limited Progression, Maintaining TKI Regimen Often Optimal Approach in Lung Cancer

November 10th 2014

How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?

Lung Cancer Treatment on Brink of New Molecular Era

November 10th 2014

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

Dr. Levy Discusses Recent Updates in Immunotherapy for Lung Cancer

November 10th 2014

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer

November 10th 2014

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

Dr. Lynch Discusses Resistance to EGFR TKIs in Lung Cancer

November 8th 2014

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

PER Conference Features Expert Views on Lung Cancer Advances

November 7th 2014

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

Dr. Papadimitrakopoulou Provides an Update on Pembrolizumab for Lung Cancer

November 7th 2014

Vassiliki Papadimitrakopoulou, MD, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Collaboration Accelerates KRAS Inhibitor Development

November 4th 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

Expert Predicts the Future of Immune Therapies for Lung Cancer

November 1st 2014

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

Dr. Patel on the Benefits of a Multidisciplinary Approach for Patients With Stage III Lung Cancer

November 1st 2014

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.

Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

November 1st 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC

November 1st 2014

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.

Expert Advises on Managing Side Effects of Targeted Lung Cancer Therapies

November 1st 2014

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

Phase II Study Shows Promising Efficacy for Nivolumab in Advanced NSCLC

October 31st 2014

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC

October 31st 2014

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Dr. Govindan on the Potential for Alectinib

October 31st 2014

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Post-Operative Radiation Therapy Improves Overall Survival in NSCLC Patients

October 31st 2014

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.